LH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-26), Labcorp Holdings's current share price is $199.65. Labcorp Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $136.09. Labcorp Holdings's Cyclically Adjusted PS Ratio for today is 1.47.
The historical rank and industry rank for Labcorp Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Labcorp Holdings's highest Cyclically Adjusted PS Ratio was 2.52. The lowest was 1.08. And the median was 1.88.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Labcorp Holdings's adjusted revenue per share data for the three months ended in Mar. 2024 was $37.504. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $136.09 for the trailing ten years ended in Mar. 2024.
The historical data trend for Labcorp Holdings's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 1.56 | 1.61 | 1.53 | 1.72 | 1.61 |
For the Diagnostics & Research subindustry, Labcorp Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Labcorp Holdings's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 199.65 | / | 136.09 | |
= | 1.47 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Labcorp Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 37.504 | / | 131.7762 | * | 131.7762 | |
= | 37.504 |
Current CPI (Mar. 2024) = 131.7762.
Labcorp Holdings Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 17.571 | 100.560 | 23.026 |
201409 | 17.940 | 100.428 | 23.540 |
201412 | 17.569 | 99.070 | 23.369 |
201503 | 19.117 | 99.621 | 25.287 |
201506 | 22.138 | 100.684 | 28.974 |
201509 | 22.520 | 100.392 | 29.560 |
201512 | 22.270 | 99.792 | 29.408 |
201603 | 22.813 | 100.470 | 29.921 |
201606 | 23.350 | 101.688 | 30.259 |
201609 | 23.019 | 101.861 | 29.779 |
201612 | 22.366 | 101.863 | 28.934 |
201703 | 23.142 | 102.862 | 29.647 |
201706 | 24.380 | 103.349 | 31.086 |
201709 | 25.279 | 104.136 | 31.989 |
201712 | 26.417 | 104.011 | 33.469 |
201803 | 27.546 | 105.290 | 34.475 |
201806 | 27.828 | 106.317 | 34.492 |
201809 | 27.569 | 106.507 | 34.110 |
201812 | 27.572 | 105.998 | 34.277 |
201903 | 28.052 | 107.251 | 34.467 |
201906 | 29.167 | 108.070 | 35.565 |
201909 | 29.791 | 108.329 | 36.239 |
201912 | 30.137 | 108.420 | 36.629 |
202003 | 29.051 | 108.902 | 35.153 |
202006 | 28.340 | 108.767 | 34.335 |
202009 | 39.716 | 109.815 | 47.659 |
202012 | 45.674 | 109.897 | 54.767 |
202103 | 42.249 | 111.754 | 49.818 |
202106 | 39.111 | 114.631 | 44.961 |
202109 | 41.839 | 115.734 | 47.638 |
202112 | 11.125 | 117.630 | 12.463 |
202203 | 41.485 | 121.301 | 45.068 |
202206 | 31.545 | 125.017 | 33.251 |
202209 | 31.607 | 125.227 | 33.260 |
202212 | 32.844 | 125.222 | 34.563 |
202303 | 34.133 | 127.348 | 35.320 |
202306 | 34.047 | 128.729 | 34.853 |
202309 | 35.136 | 129.860 | 35.655 |
202312 | 35.477 | 129.419 | 36.123 |
202403 | 37.504 | 131.776 | 37.504 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Labcorp Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter J Wilkinson | officer: SVP, Chief Accounting Officer | C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401 |
Kerrii B Anderson | director | WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017 |
Van Der Vaart Sandra D | officer: SVP, Global General Counsel | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Paul Rothman | director | 6 MEADOW ROAD, BALTIMORE MD 21212 |
Paul R Kirchgraber | officer: CEO, Covance Drug Development | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Mark S Schroeder | officer: EVP, President-Diagnostics Lab | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Megan D. Bailey | officer: EVP, Chief Strategy Officer | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Jonathan P. Divincenzo | officer: EVP, Pres, Central Labs & Intl | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Anita Z Graham | officer: EVP, CHRO | C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431 |
Thomas Pike | officer: Pres & CEO Clinical Business | C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601 |
Kirsten Marie Kliphouse | director | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
Glenn A Eisenberg | officer: Chief Financial Officer, EVP | P O BOX 1017, CHARLOTTE NC 28201-1017 |
Brian J Caveney | officer: SVP, Chief Medical Officer | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
R Sanders Williams | director | DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706 |
Amy B. Summy | officer: EVP, Chief Marketing Officer | 531 SOUTH SPRING STREET, BURLINGTON NC 27215 |
From GuruFocus
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024